LIM2551

12070505, human colon, epithelial; forms aggregates of small rounded cells, adherent and suspended.

• Synonym(e): LIM 2551, LIM-2551
• UNSPSC-Code: 41106514

Eigenschaften

• Produktbezeichnung: LIM2551, 12070505
• Biologische Quelle: human colon
• Wachstumsmodus: Semi-adherent
• Karyotyp: Not specified
• Morphologie: Epithelial; grows as loose aggregates of small rounded cells, some adherent, others in suspension.
• Rezeptoren: Not specified
• Relevante Krankheit(en): cancer

Beschreibung

Ursprung der Zelllinie

Human derived from an adenocarcinoma of the transverse colon

Beschreibung der Zelllinie

LIM2551 was derived from an adenocarcinoma of the transverse colon. Cell Bank Australia reference number: CBA0170.

DNA-Profil

Not specified

Nährmedium

RPMI 1640 (R0883) (with 2 mM L-Glutamine (G7513) + 25mM HEPES) + FBS / FCS (F2442), Insulin 0.6 μg/ml, Hydrocortisone 1 μg/ml, 1-Thioglycerol 10 μM.

Subkultur-Routine

Optimal split ratio 1:8-1:16 (seeding density 1 x 10⁴ cells/cm²). Cells incubated at 37 °C with 5% CO₂. Harvest the cells using 0.05% Trypsin/EDTA at 37 °C for 5 min. LIM2551 requires the growth medium to be changed 3 times each week. Feed and passage as for semi-adherent culture (collect medium with floating cells and then trypsinise the adherent population, pool both together before reseeding).

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments.  Please check with your local Customer Service representative for more information.

Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.

Depositor and originator: Professor Tony Burgess - Ludwig Institute for Cancer Research Ltd, Melbourne, Australia